Bienville Capital Management LLC Takes $27.24 Million Position in Hims & Hers Health, Inc. $HIMS

Key Points

• Bienville Capital Management acquired 785,739 Hims & Hers shares worth approximately $27.24 million, giving the stock a 3.6% portfolio allocation and making it the fund’s ninth-largest holding.
• Institutional ownership stands at 63.52%, but insiders sold 190,227 shares worth about $6.13 million during the last quarter, indicating notable insider selling activity.
• Hims & Hers delivered 38.2% year-over-year revenue growth to $753.21 million, beating expectations, but its $0.37 quarterly loss per share was substantially worse than expected. Analysts maintain a consensus “Hold” rating with an average price target of $32.50.

Bienville Capital Management LLC purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 785,739 shares of the company's stock, valued at approximately $27,242,000. Hims & Hers Health makes up approximately 3.6% of Bienville Capital Management LLC's portfolio, making the stock its 9th largest holding. Bienville Capital Management LLC owned 0.34% of Hims & Hers Health at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Binnacle Investments Inc purchased a new position in Hims & Hers Health in the third quarter valued at about $28,000. Versant Capital Management Inc lifted its position in shares of Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company's stock valued at $26,000 after buying an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company's stock valued at $27,000 after buying an additional 319 shares in the last quarter. Silicon Valley Capital Partners purchased a new position in shares of Hims & Hers Health in the 3rd quarter worth approximately $48,000. Finally, EverSource Wealth Advisors LLC grew its position in shares of Hims & Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company's stock worth $47,000 after buying an additional 687 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Hims & Hers Health

In other news, insider Patrick Carroll sold 23,726 shares of the firm's stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $35.00, for a total value of $830,410.00. Following the completion of the transaction, the insider directly owned 181,861 shares in the company, valued at $6,365,135. This trade represents a 11.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deborah M. Autor sold 16,773 shares of Hims & Hers Health stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $27.85, for a total value of $467,128.05. Following the sale, the insider directly owned 48,961 shares of the company's stock, valued at $1,363,563.85. This trade represents a 25.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 190,227 shares of company stock worth $6,133,613 in the last quarter. 11.76% of the stock is owned by insiders.

Hims & Hers Health Trading Down 1.3%

NYSE HIMS opened at $27.81 on Thursday. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $65.30. The company has a fifty day simple moving average of $31.23 and a two-hundred day simple moving average of $27.07. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The stock has a market cap of $6.49 billion, a P/E ratio of -44.14 and a beta of 2.42.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company had revenue of $753.21 million for the quarter, compared to analysts' expectations of $698.90 million. During the same period last year, the firm earned $0.17 earnings per share. Hims & Hers Health's quarterly revenue was up 38.2% compared to the same quarter last year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on HIMS shares. Morgan Stanley increased their target price on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an "equal weight" rating in a research report on Tuesday, August 11th. Citigroup reduced their price target on Hims & Hers Health from $35.00 to $33.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 11th. Truist Financial increased their price objective on Hims & Hers Health from $27.00 to $32.00 and gave the company a "hold" rating in a report on Monday, August 24th. Weiss Ratings reissued a "sell (d)" rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Finally, Barclays reduced their target price on Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating on the stock in a research report on Friday, August 21st. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Hims & Hers Health has an average rating of "Hold" and an average price target of $32.50.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Negative Sentiment: A securities class action has been filed on behalf of investors who purchased HIMS securities between August 4, 2025, and July 29, 2026. The lawsuit alleges that the company and certain executives violated federal securities laws by making misleading statements or omitting material information related to the FTC’s allegations. Investors have until November 2, 2026, to seek lead-plaintiff status. Kaplan Fox class action announcement
• Negative Sentiment: A wave of investor-rights firms, including Robbins LLP, Bronstein Gewirtz & Grossman, and Glancy Prongay Wolke & Rotter, is urging investors with losses to participate in the case. Although these announcements largely repeat the same lawsuit details, the concentrated legal attention reinforces concerns about possible damages, defense expenses, and management distraction. Robbins LLP class action reminder
• Negative Sentiment: One legal notice linked the lawsuit to an over-14% stock decline and allegations involving privacy and billing practices. The claims have not been proven, but they add headline risk while the FTC matter proceeds. Kahn Swick & Foti legal notice
• Neutral Sentiment: Recent earnings also remain a backdrop: Hims & Hers reported revenue growth of 38.2% year over year and exceeded revenue expectations, but its quarterly EPS loss was substantially wider than analysts expected. This mixed operating performance may limit investor support amid the legal uncertainty. Zacks earnings review

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.